Alexion Biologic Soliris Is First To Get FDA Nod For Rare Blood Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Soliris is slated to launch within two weeks from its March 16 approval.
You may also be interested in...
Alexion’s Soliris REMS Working Well But Might Benefit From Small Changes
FDA advisory committee will weigh potential tweaks to orphan drug’s risk management plan, which is meeting informational goals regarding meningococcal infections but could be burdening prescribers with repeated assessments.
Alexion’s Soliris REMS Gets FDA Panel Review In Wider Evaluation Effort
FDA advisory committee will revisit REMS for ultra-rare disease drug as part of larger agency effort to evaluate the effectiveness of the safety programs.
Alexion's Soliris Gains New Orphan Indication But Limited Sales Expectations
The devastating natural course of atypical hemolytic uremic syndrome, coupled with the small quantity of drug used to treat pediatric patients, means the new use is expected to have only a small impact on sales initially, Alexion's management says.